New Therapies for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients

Authors

  • A. Conti Dermatologic Unit Department of Surgery Infermi Hospital of Rimini AUSL Romagna Rimini Italy
  • F. Tartari Dermatologic Unit Department of Surgery Infermi Hospital of Rimini AUSL Romagna Rimini Italy

Keywords:

Atopic dermatitis, Skin barrier alterations, Dysregulated immune activity, IL13 inhibitors, JAK inhibitors, Crisaborole, Ruxolitinib, Tapinarof, Nemolizumab

Abstract

In pediatric patients with severe atopic dermatitis, novel therapeutic options
have recently become available - options that were not accessible until a few
years ago. The authors outline the principal agents currently approved for systemic
treatment, as well as those undergoing advanced clinical investigation.

Downloads

Download data is not yet available.

Author Biography

A. Conti, Dermatologic Unit Department of Surgery Infermi Hospital of Rimini AUSL Romagna Rimini Italy

Corresponding author:

Andrea Conti

Dermatologic Unit,

Department of Surgery,

Infermi Hospital of Rimini,

AUSL Romagna,

Viale Settembrini 2,

47923 Rimini (RN), Italy

e-mail: a.conti.dermo@gmail.com

Published

2026-01-14

How to Cite

Conti, A., & Tartari, F. (2026). New Therapies for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients. International Journal of Pediatric Dermatology, 2(3), 106–110. Retrieved from https://scientificeditorial.com/index.php/IJPD/article/view/New-Therapies-for-Moderate-to-Severe-Atopic-Dermatitis-in-Pediat

Issue

Vol. 2 No. 3 (2025): International Journal of Pediatric Dermatology. Special Issue

Section

REVIEW
Copyright & Licensing